Web24 mar 2024 · Drug: ZN-c3: Phase 2: Detailed Description: This is a Phase 2 open-label, multicenter study to evaluate the clinical activity, safety, pharmacokinetics (PK), and … Web19 dic 2024 · Drug: ZN-c3 Detailed Description This is an open-label multicenter Phase 1/2 dose escalation study, evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of the novel BCL-2 inhibitor ZN-d5 and Wee1 inhibitor ZN-c3 in subjects with AML.
ZN-c3 was safe and well-tolerated - GlobeNewswire News …
Web11 ago 2024 · A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer This is a Phase … Web26 gen 2024 · ZN-c3 in Adult Participants With Metastatic Colorectal Cancer March 8, 2024 updated by: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, … cities skylines full mod indir
Zentalis Pharmaceuticals Announces FDA Clearance of the IND for …
Web18 dic 2024 · We believe these characteristics will provide for a differentiated drug product to help fight cancer, if ZN-c3 is approved. There is currently no FDA-approved WEE1 inhibitor. The Company is evaluating the potential of ZN-c3 in a Phase 1/2 clinical trial as monotherapy and in combination with an FDA-approved PARP inhibitor. Web20 giu 2024 · Drug: ZN-c3. Given by PO 1 time a day with a glass (about 8 ounces) of water; Drug: Bevacizumab. Given by vein over about 30-60 minutes on Day 1 of each cycle; Drug: Pembrolizumab. Given by vein over 30-60 minutes on Day 1 of each cycle. Arms, Groups and Cohorts. Experimental: Regimen A. ZN-c3 in combination with … Web15 apr 2024 · The drug, ZN-c3, shrank tumors in two patients enough for them to be considered responders: One patient had stage 4 ovarian cancer and had tried 18 lines of treatment, while the other patient had stage 4 colorectal cancer and had undergone five prior lines of treatment, according to data presented virtually at the American Association for … diary of a wimpy kid read